Base de dados : MEDLINE
Pesquisa : D02.065.199.092.450 [Categoria DeCS]
Referências encontradas : 543 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 55 ir para página                         

  1 / 543 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28105852
[Au] Autor:Janícková O; Ancicová L; Briestenská K; Mistríková J
[Ti] Título:The effect of Isoprinosine treatment on persistent infection of Balb/c mice infected with murine gammaherpesvirus 68.
[So] Source:Acta Virol;61(1):32-38, 2017.
[Is] ISSN:0001-723X
[Cp] País de publicação:Slovakia
[La] Idioma:eng
[Ab] Resumo:We demonstrated the positive effect of Isoprinosine treatment on persistent infection of Balb/c mice with murine gammaherpesvirus 68 (MHV-68). Increased number of leukocytes, increased percentage of neutrophils, elevated levels of virus-neutralizing (VN) antibodies, reduced number of atypical lymphocytes and reduced virus titers were detected in the examined organs after a 14-day treatment. The positive effect of Isoprinosine therapy vanished after 120-150 days. After this interval, we demonstrated lower numbers of leukocytes, lower levels of VN antibodies and an increased number of atypical lymphoid monocytes in the Isoprinosine-treated group. Immunological parameters correlated with increased titers of virus in all investigated organs. Evidence of immunostimulation was demonstrated by lower incidence of tumor formation (7.5%) in the group of MHV-infected and Isoprinosine-treated mice in comparison to group without Isoprinosine treatment (17.5%). The presented results showed that Isoprinosine therapy had a positive impact on persistent infection of mice with MHV-68, but this effect was time-limited. The improvement of the investigated parameters lasted for five months only. Our presented results confirmed that each treatment with Isoprinosine should be repeated and must be long-term in some chronic infections.
[Mh] Termos MeSH primário: Antivirais/uso terapêutico
Gammaherpesvirinae
Infecções por Herpesviridae/tratamento farmacológico
Inosina Pranobex/uso terapêutico
[Mh] Termos MeSH secundário: Animais
Cercopithecus aethiops
Macrófagos Peritoneais/virologia
Camundongos
Camundongos Endogâmicos BALB C
Células NIH 3T3
Células Vero
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antiviral Agents); W1SO0V223F (Inosine Pranobex)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170629
[Lr] Data última revisão:
170629
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170121
[St] Status:MEDLINE
[do] DOI:10.4149/av_2017_01_32


  2 / 543 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28146624
[Au] Autor:Majewska A; Lasek W; Przybylski M; Dzieciqtkowski T; Mlynarczyk G
[Ti] Título:Interferon-α and inosine pranobex-mediated inhibition of reploication of human RNA viruses in vitro.
[So] Source:Med Dosw Mikrobiol;68(1):64-71, 2016.
[Is] ISSN:0025-8601
[Cp] País de publicação:Poland
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Interferon- a (IFN-a), produced by immune cells, exhibits pleiotropic anti- viral activity. Inosine pranobex (PI), a synthetic derivative of a purine, shows direct anti- viral activity, and also acts indirectly, by activation of immune cells. The aim of this study was to evaluate an in vitro inhibition of Coxackievirus A16 (CAI6), enterovirus 71 (EV71) and human parainfluenza virus 4 (HPIV-4) replication by PI in combination with IFN-a. MATERIALS AND METHODS: In the present study we evaluated an in vitro effect of interferon-a and inosine pranobex on replication ofRNAviruses: CA-16, EV71, HPIV-4. Antiviral effects of IFN-a and IPwere assessed by phenotypic assays. The yield reduction assay (YRA), which evaluates the ability of the compounds to inhibit virus multiplication in cell cultures, was ap- plied. The Reed-Muench statistical method was used to determine the 50% end point (IC51). RESULTS: Our studies have shown that combination of IFN-a and inosine pranobex dis- play higher efficacy than treatment with either compound alone, and suggest syn- ergy that may increase therapeutic effectiveness. The reduction of the average viral ti- ters of EV71, CA-16 and HPIV-4 in A549 cell culture after applying 400 Ig/mL Ip and IFN-a (1000 IU/mL), in comparison to the viral titer in the control was reduced by 1,76 log,, TCID,,/ml, o 3,00 log, TCID50/ml , and 1,60 log,( TCID50/ml respec- tively. The antiviral activity of the tested compounds was also analyzed on the basis of IC., values. Application of 1000 IU/ml IFN-a, with PI after infection of A549 cells with mention above viruses reduced the IC,, by 3,5%, 41,3% and 29% respectively. CONCLUSIONS: Our study demonstrated that enhanced antiviral activity was observed when cells infected with RNA viruses were treated with combination of IFN-a and IP. The ef- fectiveness of IFN-a and IP under these conditions has not been previously reported. CA16 virus turned out to be the most sensitive to the action of used inhibitors.
[Mh] Termos MeSH primário: Antivirais/farmacologia
Inosina Pranobex/farmacologia
Interferon-alfa/farmacologia
Vírus de RNA/fisiologia
Replicação Viral/efeitos dos fármacos
[Mh] Termos MeSH secundário: Seres Humanos
Vírus de RNA/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antiviral Agents); 0 (Interferon-alpha); W1SO0V223F (Inosine Pranobex)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170317
[Lr] Data última revisão:
170317
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170202
[St] Status:MEDLINE


  3 / 543 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27821093
[Au] Autor:Beran J; Salapová E; Spajdel M; Isoprinosine Study (EWO ISO-2014/1) Team
[Ad] Endereço:Vaccination and Travel Medicine Centre, Tylovo nábrezí 418/6, 500 02, Hradec Králové, Czech Republic. jiri.beran@vakcinace.cz.
[Ti] Título:Inosine pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: analysis and subgroup analysis from a Phase 4, randomised, placebo-controlled, double-blind study.
[So] Source:BMC Infect Dis;16(1):648, 2016 Nov 07.
[Is] ISSN:1471-2334
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Inosine pranobex (Isoprinosine®) is an immunomodulatory drug approved in several countries for the treatment of viral infections. This study compared the efficacy and safety of inosine pranobex versus placebo in subjects with clinically diagnosed influenza-like illness, including subjects with laboratory-confirmed acute respiratory viral infections. Subgroup analyses evaluated the efficacy of inosine pranobex compared to placebo in otherwise healthy (without related ongoing disease) subjects that were less than 50 years of age and healthy subjects that were at least 50 years of age. The effect of body mass index (BMI) was evaluated in subjects less than 50 years of age. METHODS: A total of 463 subjects were randomly assigned to receive inosine pranobex (n = 231) or placebo (n = 232) in this Phase 4, randomised, double-blind, multicentre study. The primary efficacy endpoint was time to resolution of all influenza-like symptoms present at baseline to none. Safety was evaluated through analysis of adverse events, vital signs, and physical examinations. RESULTS: The difference in time to resolution of all influenza-like symptoms between treatment groups was not statistically significant but showed a faster improvement in subjects in the inosine pranobex group versus those in the placebo group - Hazard Ratio = 1.175; (95 % CI: 0.806-1.714). P-value = 0.324. In the subgroup analysis for subjects less than 50 years of age, statistically significant differences in time to resolution of influenza-like symptoms that favoured the inosine pranobex group over the placebo group were observed in those without related ongoing disease and those who were non-obese (BMI <30 kg/m ). The differences between the inosine pranobex and placebo groups in subjects at least 50 years of age without related ongoing disease and in subjects less than 50 years of age who were obese (BMI ≥30 kg/m ) were not statistically significant. Inosine pranobex was generally well tolerated, and no deaths were reported. CONCLUSIONS: The study results indicate the safety of inosine pranobex for the treatment of subjects with confirmed acute respiratory viral infections and confirm the efficacy of inosine pranobex versus placebo in healthy non-obese subjects less than 50 years of age with clinically diagnosed influenza-like illnesses. TRIAL REGISTRATION: EWO-ISO-2014/1, EudraCT 2014-001863-11 ; Date of registration: 29 APR 2014; Detail information web link: https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001863-11/results.
[Mh] Termos MeSH primário: Antivirais/uso terapêutico
Influenza Humana/tratamento farmacológico
Inosina Pranobex/uso terapêutico
[Mh] Termos MeSH secundário: Doença Aguda
Adulto
Antivirais/toxicidade
Método Duplo-Cego
Feminino
Seres Humanos
Inosina Pranobex/toxicidade
Masculino
Meia-Idade
Resultado do Tratamento
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE IV; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Antiviral Agents); W1SO0V223F (Inosine Pranobex)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170614
[Lr] Data última revisão:
170614
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161109
[St] Status:MEDLINE


  4 / 543 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27479194
[Au] Autor:Pavlova EL; Zografov NN; Simeonova LS
[Ad] Endereço:Biophysics & Medical Physics, Sofia University "St. Kliment Ohridski", 5 James Boucher Blvd., 1164 Sofia, Bulgaria. Electronic address: elli_pavlova@abv.bg.
[Ti] Título:Comparative study on the antioxidant capacities of synthetic influenza inhibitors and ellagic acid in model systems.
[So] Source:Biomed Pharmacother;83:755-762, 2016 Oct.
[Is] ISSN:1950-6007
[Cp] País de publicação:France
[La] Idioma:eng
[Ab] Resumo:This study compares the antioxidant capacities in vitro of several synthetic and natural compounds applied and researched for influenza treatment - oseltamivir, isoprinosine, ellagic acid, vitamin E and vitamin C. Three chemical systems are utilized for the generation of reactive oxygen species (ROS) at pH 7.4 and pH 8.5: (1) Fenton's (Fe +H O ) for OH and -OH species (2) H O (3) NADH-phenazinemethosulfat, for superoxide radicals (O ). The kinetics was evaluated by lucigenin-enhanced chemiluminescence. The calculated constants of inhibition k describe the antioxidant capacity at the moment of oxidative burst. Their values do not necessarily correspond to the calculated total antioxidant activity. The obtained results revealed that the synthetic anti-influenza drugs (oseltamivir and isoprinosine) as well as ellagic acid possess pronounced scavenging properties mostly against superoxide radicals, comparable and higher than that of traditional natural antioxidants. Quantitative analysis of the antioxidant effects of the examined synthetic substances was performed. The results compared the corresponding effect of the average physiological concentrations and the applied therapeutic antioxidant dose. With these experiments we registered new aspects of their therapeutic activities, due to antioxidant properties against hydroxyl, superoxide radicals and H O oxidation.
[Mh] Termos MeSH primário: Antioxidantes/farmacologia
Antivirais/farmacologia
Ácido Elágico/farmacologia
Modelos Biológicos
[Mh] Termos MeSH secundário: Ácido Ascórbico/farmacologia
Peróxido de Hidrogênio/química
Peróxido de Hidrogênio/metabolismo
Inosina Pranobex/farmacologia
Ferro/química
Cinética
Medições Luminescentes
NAD/metabolismo
Oseltamivir/farmacologia
Oxirredução
Padrões de Referência
Vitamina E/farmacologia
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antioxidants); 0 (Antiviral Agents); 0 (Fenton's reagent); 0U46U6E8UK (NAD); 1406-18-4 (Vitamin E); 19YRN3ZS9P (Ellagic Acid); 20O93L6F9H (Oseltamivir); BBX060AN9V (Hydrogen Peroxide); E1UOL152H7 (Iron); PQ6CK8PD0R (Ascorbic Acid); W1SO0V223F (Inosine Pranobex)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170809
[Lr] Data última revisão:
170809
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160802
[St] Status:MEDLINE


  5 / 543 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27476281
[Au] Autor:Majewska A; Lasek W; Janyst M; Mlynarczyk G
[Ti] Título:IN VITRO INfIBITION OF HHV-1 REPLICATION BY INOSINE PRANOBEX AND INTERFERON-α.
[So] Source:Acta Pol Pharm;73(3):637-44, 2016 May-Jun.
[Is] ISSN:0001-6837
[Cp] País de publicação:Poland
[La] Idioma:eng
[Ab] Resumo:Key issues in the development of novel antivirals are the emergence of resistant strains. The development of new drugs effective against herpes diseases has proven to be both difficult and time-consuming. Some alternative may be to optimize the efficacy and selectivity of existing antiviral drugs or combining them with other well known agents. Inosine pranobex exerts a direct antiviral effect as well as secondary effect to its immunomodulatory activity. We found that increasing concentrations of inosine pranobex (50-400 µg/mL) produced progressively growing inhibitory effect on HHV-1 replication, following infection of different cell lines. The combination of 1000 IU/mL IFN-α and inosine pranobex also resulted in enhanced anti-HHV activity. Immunotherapy may be beneficial for patients from whom strains resistant to currently known antiviral drugs have been isolated.
[Mh] Termos MeSH primário: Antivirais/farmacologia
Herpesvirus Humano 1/efeitos dos fármacos
Inosina Pranobex/farmacologia
Interferon-alfa/farmacologia
Replicação Viral/efeitos dos fármacos
[Mh] Termos MeSH secundário: Aciclovir/farmacologia
Linhagem Celular
Sobrevivência Celular/efeitos dos fármacos
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antiviral Agents); 0 (Interferon-alpha); W1SO0V223F (Inosine Pranobex); X4HES1O11F (Acyclovir)
[Em] Mês de entrada:1609
[Cu] Atualização por classe:160801
[Lr] Data última revisão:
160801
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160802
[St] Status:MEDLINE


  6 / 543 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27344315
[Au] Autor:Barkin JA; Czul F; Barkin JS; Klimas NG; Rey IR; Moshiree B
[Ad] Endereço:Division of Gastroenterology, Department of Medicine, Leonard M. Miller School of Medicine, University of Miami, 1120 NW 14th Street, Clinical Research Building, Suite 1116 (D-49), Miami, FL, 33136, USA. jabarkin@med.miami.edu.
[Ti] Título:Gastric Enterovirus Infection: A Possible Causative Etiology of Gastroparesis.
[So] Source:Dig Dis Sci;61(8):2344-50, 2016 Aug.
[Is] ISSN:1573-2568
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Gastroparesis (GP) is a disabling chronic gastroenterologic disorder with high morbidity that severely impacts patients' quality of life. GP can present acutely after a viral-like gastrointestinal illness resulting in speculation that in some patients, neurologic damage caused by the infection might underlie the pathogenesis of idiopathic gastroparesis (IGP). AIMS: The aim of this study is to document case reports of Enterovirus (EV) infection as a possible cause of IGP. METHODS: Eleven patients referred with a diagnosis of GP underwent workup to exclude known causes of GP. Those with a history of flu-like symptoms or gastroenteritis prior to onset of GP symptoms had gastric biopsies taken during upper endoscopy to assess for the presence of gastric mucosal EV infection. Data on presenting symptoms, extra-intestinal symptoms and conditions, prior nutritional support requirements, upper endoscopy findings, and response to therapy were cataloged. RESULTS: Eleven patients were diagnosed as IGP. Nine had active EV infection on gastric biopsies and were included (7/9 female, mean age 43 years). Eight out of nine received EV treatment with antivirals and/or immune therapies, with a wide degree of variability in treatment regimens. Four out of eight who received EV treatment had symptomatic improvement. One patient had stable symptoms. Three patients are currently undergoing therapy. CONCLUSIONS: Gastric EV infection was frequently detected (82 %) in patients undergoing investigation for IGP. Antiviral and/or immune therapies against EV seem to be favorable, as most of our patients had resolution of their GP symptoms after treatment. This is the first study to identify EV as a possible infectious etiology of IGP.
[Mh] Termos MeSH primário: Infecções por Enterovirus/epidemiologia
Gastrite/epidemiologia
Gastroparesia/epidemiologia
[Mh] Termos MeSH secundário: 2-Aminopurina/análogos & derivados
2-Aminopurina/uso terapêutico
Adulto
Idoso
Antivirais/uso terapêutico
Biópsia
Infecções por Enterovirus/patologia
Infecções por Enterovirus/terapia
Feminino
Gastrite/patologia
Gastrite/terapia
Refluxo Gastroesofágico/epidemiologia
Gastroparesia/terapia
Gastroparesia/virologia
Seres Humanos
Imunoglobulinas Intravenosas/uso terapêutico
Fatores Imunológicos/uso terapêutico
Inosina Pranobex/uso terapêutico
Masculino
Meia-Idade
Síndrome da Taquicardia Postural Ortostática/epidemiologia
Ribavirina/uso terapêutico
Estômago/patologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antiviral Agents); 0 (Immunoglobulins, Intravenous); 0 (Immunologic Factors); 452-06-2 (2-Aminopurine); 49717AWG6K (Ribavirin); QIC03ANI02 (famciclovir); W1SO0V223F (Inosine Pranobex)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:171019
[Lr] Data última revisão:
171019
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:160627
[St] Status:MEDLINE
[do] DOI:10.1007/s10620-016-4227-x


  7 / 543 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27002696
[Au] Autor:Rabinovich OF; Rabinovich IM; Abramova ES
[Ad] Endereço:Central Research Institute of Dental and Maxillofacial Surgery, Ministry of Health of Russia, Moscow, Russia.
[Ti] Título:[Optimization of complex treatment of patients with severe oral leukoplakia].
[So] Source:Stomatologiia (Mosk);94(6):19-21, 2015.
[Is] ISSN:0039-1735
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:The aim of the study was to prove the rationale for antiviral therapy combined with surgical procedures for treatment of severe oral leukoplakia. Complex clinical and laboratory evaluation and treatment was performed in 56 patients divided in 2 groups. Control group was presented by 13 patients receiving dental treatment, local and systemic keratoplastic formulations. Main group involved 43 patients in which conventional treatment protocol was completed by antiviral therapy and surgical procedures. Leukoplakia diagnosis was based on clinical findings, histological and immunohistochemical studies as well as optic coherent tomography data. The obtained results evidently prove the necessity for including antiviral therapy and surgical procedures in treatment scheme of severe oral leukoplakia.
[Mh] Termos MeSH primário: Antivirais/uso terapêutico
Inosina Pranobex/uso terapêutico
Leucoplasia Bucal/terapia
Peptídeos/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Terapia Combinada
Feminino
Seres Humanos
Imuno-Histoquímica
Leucoplasia Bucal/tratamento farmacológico
Leucoplasia Bucal/patologia
Leucoplasia Bucal/cirurgia
Masculino
Meia-Idade
Índice de Gravidade de Doença
Tomografia de Coerência Óptica
[Pt] Tipo de publicação:CONTROLLED CLINICAL TRIAL; ENGLISH ABSTRACT; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Alloferon); 0 (Antiviral Agents); 0 (Peptides); W1SO0V223F (Inosine Pranobex)
[Em] Mês de entrada:1604
[Cu] Atualização por classe:170621
[Lr] Data última revisão:
170621
[Sb] Subgrupo de revista:D; IM
[Da] Data de entrada para processamento:160323
[St] Status:MEDLINE
[do] DOI:10.17116/stomat201594619-21


  8 / 543 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:26859953
[Au] Autor:Breusov AA; Kulchavenya EV; Brizhatyukl EV; Filimonov PN
[Ti] Título:[OPTIMAL APPROACH TO COMBINED TREATMENT OF PATIENTS WITH UROGENITAL PAPILLOMATOSIS].
[So] Source:Urologiia;(5):118-20, 122-3, 2015 Sep-Oct.
[Is] ISSN:1728-2985
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:The review analyzed 59 sources of domestic and foreign literature on the use of immunomodulator izoprinozin in treating patients infected with human papilloma virus, and the results of their own experience. The high prevalence of HPV and its role in the development of cervical cancer are shown, the mechanisms of HPV development and the host protection from this infection are described. The authors present approaches to the treatment of HPV-infected patients with particular attention to izoprinozin. Isoprinosine belongs to immunomodulators with antiviral activity. It inhibits the replication of viral DNA and RNA by binding to cell ribosomes and changing their stereochemical structure. HPV infection, especially in the early stages, may be successfully cured till the complete elimination of the virus. Inosine Pranobex (izoprinozin) having dual action and the most abundant evidence base, may be recognized as the optimal treatment option.
[Mh] Termos MeSH primário: Antivirais/uso terapêutico
Condiloma Acuminado/terapia
Inosina Pranobex/uso terapêutico
Papillomaviridae
[Mh] Termos MeSH secundário: Terapia Combinada
Condiloma Acuminado/patologia
Feminino
Seres Humanos
[Pt] Tipo de publicação:ENGLISH ABSTRACT; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antiviral Agents); W1SO0V223F (Inosine Pranobex)
[Em] Mês de entrada:1602
[Cu] Atualização por classe:160210
[Lr] Data última revisão:
160210
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160211
[St] Status:MEDLINE


  9 / 543 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:26591662
[Au] Autor:Majewska A; Lasek W; Mlynarczyk G
[Ti] Título:[Inosine pranobex - cytotoxic activities and effect of on replication of human parainfluenza viruses (HPIV-2, HPIV-4), entroviruses (CA16, EV71) and adenoviruses (HAdV-2, HAdV-5) in vitro].
[Ti] Título:Pranobeks inozyny - dzialanie cytotoksyczne oraz wplyw na replikacje ludzkich wirusów paragrypy (HPIV-2, HPIV-4), enterowirusów (CA16, EV71) i adenowirusów (HAdV-2, HAdV-5) w badaniu in vitro..
[So] Source:Med Dosw Mikrobiol;67(2):107-13, 2015.
[Is] ISSN:0025-8601
[Cp] País de publicação:Poland
[La] Idioma:pol
[Ab] Resumo:INTRODUCTION: There are no specific antivirals designed for many viral infections. Inosine pranobex (PI) is a purine nucleoside that is involved in a wide variety of intracellular biochemical processes. The mechanism of action in human body is still unclear but numerous studies have demonstrated that this drug inhibits viral replication and exhibit pleiotropic effect. We evaluated in vitro effect of inosine pranobex (PI) on replication of human viruses: parainfluenza viruses (HPIV-2, HPIV-4), entroviruses A (CA16, EV71) and adenoviruses C (HAdV-2, HAdV-5). MATERIALS AND METHODS: In the present study, cytotoxic effect of inosine pranobex was assessed using A549 cell line exposed to different concentrations of compound (PI: 50-800 ig/mL) for 48 hours. Cytotoxic effect of inosine pranobex was assessed visually using light, inverted microscopy Olympus CK2 under 400x magnification and by the MTT colorimetric assay. Antiviral effect was estimated according to the reduction of virus titer. The yield reduction assay (YRA), which evaluates the ability of the PI (50-800 µg/mL) to inhibit virus multiplication in cell cultures, was applied. The cytopathic effect of the virus was evaluated 48 h after infection ofA549 cell cultures with viruses by means of light, inverted microscopy. The Reed-Muench statistical method was used to determine the 50% end point (IC50) (yield reduction assay, YRA) in the presence of inosine pranobex with the controlled one. RESULTS: There were no morphological changes, as assessed visually, in cell cultures treated with PI. MTT cytotoxicity assay confirmed microscopic observations. The viability of cells in the presence of the tested compounds was average 98, 36 %. After conducting the experiments and analyzing the results we noticed that higher concentrations of PI strongly inhibited multiplication of all viruses. PI weakly reduced the titer of infectious enteroviruses and HPIV-4 as compared with the control. Adenoviruses showed the highest sensitivity to the antiviral activity of PI, however, increasing concentrations of PI up to 800 µg /ml slightly enhanced the antiviral activity of 400 µg/ml PI. CONCLUSIONS: Our study demonstrated that inosine pranobex shows no cytotoxic activity on the A549 cell line. In conducted study was observed that adenoviruses (HAdV-2 and HAdV-5) and HPIV-2 have the highest sensitivity to the antiviral activity of inosine pranobex from all tested viral strains.
[Mh] Termos MeSH primário: Adenoviridae/efeitos dos fármacos
Antivirais/farmacologia
Enterovirus/efeitos dos fármacos
Inosina Pranobex/farmacologia
Vírus da Parainfluenza 2 Humana/efeitos dos fármacos
Vírus da Parainfluenza 4 Humana/efeitos dos fármacos
Replicação Viral/efeitos dos fármacos
[Mh] Termos MeSH secundário: Adenoviridae/crescimento & desenvolvimento
Técnicas de Cultura de Células
Linhagem Celular
Seres Humanos
Carga Viral/efeitos dos fármacos
[Pt] Tipo de publicação:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antiviral Agents); W1SO0V223F (Inosine Pranobex)
[Em] Mês de entrada:1601
[Cu] Atualização por classe:151120
[Lr] Data última revisão:
151120
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151124
[St] Status:MEDLINE


  10 / 543 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26479761
[Au] Autor:Häusler M; Aksoy A; Alber M; Altunbasak S; Angay A; Arsene OT; Craiu D; Hartmann H; Hiz-Kurul S; Ichiyama T; Iliescu C; Jocic-Jakubi B; Korinthenberg R; Köse G; Lukban MB; Ozkan M; Patcheva I; Teichler J; Vintan M; Yaramis A; Yarar C; Yis U; Yuksel D; Anlar B
[Ad] Endereço:Division of Pediatric Neurology and Social Pediatrics, Department of Pediatrics, University Hospital RWTH Aachen, Aachen, Germany.
[Ti] Título:A Multinational Survey on Actual Diagnostics and Treatment of Subacute Sclerosing Panencephalitis.
[So] Source:Neuropediatrics;46(6):377-84, 2015 Dec.
[Is] ISSN:1439-1899
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Subacute sclerosing panencephalitis (SSPE) is a chronic infection of the central nervous system caused by the measles virus (MV). Its prevalence remains high in resource poor countries and is likely to increase in the Northern Europe as vaccination rates decrease. Clinical knowledge of this devastating condition, however, is limited. We therefore conducted this multinational survey summarizing experience obtained from more than 500 patients treated by 24 physicians in seven countries. SSPE should be considered in all patients presenting with otherwise unexplained acquired neurological symptoms. In most patients, the diagnosis will be established by the combination of typical clinical symptoms (characteristic repetitive myoclonic jerks), a strong intrathecal synthesis of antibodies to MV and typical electroencephalogram findings (Radermecker complexes). Whereas the therapeutic use of different antiviral (amantadine, ribavirin) and immunomodulatory drugs (isoprinosine, interferons) and of immunoglobulins has been reported repeatedly, optimum application regimen of these drugs has not been established. This is partly due to the absence of common diagnostic and clinical standards focusing on neurological and psychosocial aspects. Carbamazepine, levetiracetam, and clobazam are the drugs most frequently used to control myoclonic jerks. We have established a consensus on essential laboratory and clinical parameters that should facilitate collaborative studies. Those are urgently needed to improve outcome.
[Mh] Termos MeSH primário: Antivirais/uso terapêutico
Inosina Pranobex/uso terapêutico
Interferons/uso terapêutico
Panencefalite Esclerosante Subaguda/diagnóstico
[Mh] Termos MeSH secundário: Anticonvulsivantes/uso terapêutico
Ásia
Carbamazepina/uso terapêutico
Eletroencefalografia
Europa (Continente)
Seres Humanos
Vírus do Sarampo/isolamento & purificação
Mioclonia/tratamento farmacológico
Mioclonia/etiologia
Panencefalite Esclerosante Subaguda/complicações
Panencefalite Esclerosante Subaguda/tratamento farmacológico
Inquéritos e Questionários
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anticonvulsants); 0 (Antiviral Agents); 33CM23913M (Carbamazepine); 9008-11-1 (Interferons); W1SO0V223F (Inosine Pranobex)
[Em] Mês de entrada:1609
[Cu] Atualização por classe:151124
[Lr] Data última revisão:
151124
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151020
[St] Status:MEDLINE
[do] DOI:10.1055/s-0035-1564618



página 1 de 55 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde